Metropolis Network Expansion and Revenue Growth Strategy
6. Reported EBIDTA Margins @ 22.5%
25.5%
-0.4%
Q3FY23 Reported EBIDTA
EBIDTA dilution on account of Network Expansion in Q3FY24 @1.2%
EBIDTA dilution on account of Network Expansion in Q3FY23 @0.8%
Net impact on account of dilution 0.4%
-1.4%
-0.8%
-0.4%
METROPOLIS
The Pathology Specialist
22.5%
Dilution on account
of Network Expansion
Dilution on account of
loss of PPP revenue
Dilution on account
of one time PDD
Others
Q3FY24 Reported EBIDTA
Impact on Margins on account of:
Negative operating leverage on
account of loss in revenue from a
large PPP contract
Negligible Covid & Allied Revenue;
however related cost from the
previous year persist in the system
Dilution of EBIDTA margins ~120 bps in
Q3FY24 is on account of Aggressive
Network Expansion strategy
One time impact of ~80 bps on account
of Provision for Doubtful Debt (PDD)
adjustment
Additional Impact on Margins on
account of :
•
Increased cost on Marketing
Increased cost on Information
Technology
Increased cost on customer service
Combination of higher productivity of new network, increased utilization of labs, higher operating leverage along
with organic growth should result in an uptick in margins from current levels
15View entire presentation